Finzati - Logo
JNJ logo

Johnson & Johnson

JNJ • Drug Manufacturers - General
$275.23
▼ -3.20 (-1.15%)
Current price
EarningsLatest report: Mar 29, 2026
FAVORABLE PROFILEAttractiveConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Strong business quality with supportive growth and cash-flow evidence. Valuation still matters, but the historical ratio profile is favorable.
Market Cap
$672.99B
Growth
7.4%
Cash Flow
5/5
Trend
Stable
Evidence
Stable or improving margins · 28.5%Positive revenue growth · 6.7%Positive free cash flow · 8.11Consistent free cash flow · 5/5Reasonable earnings multiple · 18.81
Financial data as of: Mar 29, 2026, 12:00 AM UTCLast earnings update: Apr 14, 2026, 12:00 AM UTCLast profile update: Aug 5, 2026, 2:36 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$275.23
Change-1.15%
Shares Out2.45B
Market Cap$672.99B
Enterprise Value$668.40B
52W Range151.01 - 251.71
Beta0.26
P/E31.99
P/S6.98
P/B8.29
P/FCF37.84
EV/Sales6.94

Investment DNA

How strong this company looks for long-term investors

79
out of 100
Business Quality
Margins, moat, returns
90/100
Financial Strength
Debt, cash, stability
65/100
Growth Potential
Revenue and expansion
63/100
Price Attractiveness
Cheap or expensive today
63/100
Why this score▼
Stable or improving margins · 28.5%Positive revenue growth · 6.7%Positive free cash flow · 8.11Consistent free cash flow · 5/5Reasonable earnings multiple · 18.81Manageable debt level · 0.59

Analyst view

Analyst sentiment and price target

JNJ
Analyst sentiment
Based on 40 analyst votes · 2026-09-05
73/100
Bullish
Bullish
21
Hold
16
Bearish
3
Price Target
2026-06-26
Low
$208.00
Mean
$251.55
Median
$255.00
High
$283.00

Company Overview

IPO: 1/2/1962
Industry: Drug Manufacturers - General
P/B i: 8.29
Debt / Equity i: 0.59
Operating Margin: 27.17%
Net Margin: 28.46%
ROE i: -
ROIC: -

Financial Health

Score13 / 20
Debt / Equity: 0.59
Current Ratio: 1.03
Quick Ratio: 0.77
Status: Good

Insider Transactions

Recent executive and insider activity

Wengel Kathryn E
Transaction: 06/11/2026
SELL
Change
-10,000
Price
$115.67
Filing
06/12/2026
Type
SELL
Wengel Kathryn E
Transaction: 06/11/2026
SELL
Change
-10,000
Price
$241.15
Filing
06/12/2026
Type
SELL
HEWSON MARILLYN A
Transaction: 06/09/2026
BUY
Change
—
Price
Not reported
Filing
06/11/2026
Type
BUY